SCHEDULE 13G: Tasso Partners and Dana Carrera Disclose 18.9% Passive Stake in PAVmed Inc.
Beneficial Ownership Report
Tasso Partners, LLC and Dana Carrera have jointly reported a beneficial ownership of 18.9% in PAVmed Inc.'s common stock, totaling 2,574,350 shares, as a passive investment.
Summary
- Tasso Partners, LLC and Dana Carrera (the "Reporting Persons") have filed a Schedule 13G, disclosing their beneficial ownership in PAVmed Inc.'s common stock.
- The Reporting Persons collectively beneficially own 2,574,350 shares of PAVmed Inc. common stock.
- This ownership represents 18.9% of the outstanding common stock of PAVmed Inc.
- The percentage of beneficial ownership is calculated based on 11,068,566 shares of common stock outstanding as of November 25, 2024, as reported in the Company's Form S-3 filed on December 20, 2024.
- The reported beneficial ownership excludes 53,974 shares of common stock issuable upon the exercise of warrants that are not currently exercisable and will not become exercisable within 60 days.
- Both Tasso Partners, LLC and Dana Carrera hold sole voting power and sole dispositive power over the 2,574,350 shares.
- Dana Carrera controls Tasso Capital, LLC, which in turn controls Tasso Partners, LLC.
- The Reporting Persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of PAVmed Inc.
Sentiment
Score: 5
Explanation: The document is a factual regulatory disclosure of beneficial ownership and does not contain information that would inherently convey positive or negative sentiment regarding the company's performance or outlook.
Positives
- A significant beneficial ownership stake (18.9%) by Tasso Partners, LLC and Dana Carrera indicates a substantial investment in PAVmed Inc.'s common stock.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: The disclosure provides transparency regarding a significant beneficial owner, which can influence perceptions of ownership concentration and stability.
Key Dates
| Date | Description |
|---|---|
| 11/25/2024 | Date as of which 11,068,566 shares of common stock outstanding were reported for beneficial ownership calculation. |
| 12/20/2024 | Date PAVmed Inc. filed its registration statement on Form S-3, which provided the shares outstanding figure. |
| 02/21/2025 | Date of event which requires the filing of this statement (acquisition of beneficial ownership). |
| 02/28/2025 | Date the Schedule 13G was signed and filed by the Reporting Persons. |
Keywords
PAVmed Inc., Tasso Partners, Dana Carrera, Schedule 13G, beneficial ownership, common stock, SEC filing, passive investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.